Allspring Global Investments Holdings LLC lessened its stake in shares of Hamilton Lane Incorporated (NASDAQ:HLNE – Get Rating) by 52.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,673 shares of the company’s stock after selling 7,454 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Hamilton Lane were worth $397,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HLNE. Bank of New York Mellon Corp increased its position in Hamilton Lane by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 187,549 shares of the company’s stock valued at $14,494,000 after buying an additional 3,340 shares in the last quarter. American Century Companies Inc. increased its position in Hamilton Lane by 13.8% during the 1st quarter. American Century Companies Inc. now owns 5,518 shares of the company’s stock valued at $426,000 after buying an additional 670 shares in the last quarter. US Bancorp DE increased its position in Hamilton Lane by 373.9% during the 1st quarter. US Bancorp DE now owns 3,109 shares of the company’s stock valued at $241,000 after buying an additional 2,453 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Hamilton Lane by 321.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 611 shares of the company’s stock valued at $48,000 after purchasing an additional 466 shares during the last quarter. Finally, Natixis Advisors L.P. purchased a new stake in Hamilton Lane during the 1st quarter valued at $805,000. Institutional investors own 63.52% of the company’s stock.
Analyst Ratings Changes
Several analysts have commented on the company. UBS Group cut their target price on Hamilton Lane from $75.00 to $68.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Wells Fargo & Company increased their target price on Hamilton Lane from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 11th. Finally, Morgan Stanley increased their target price on Hamilton Lane from $67.00 to $72.00 and gave the company an “equal weight” rating in a research note on Tuesday.
Hamilton Lane Stock Performance
Hamilton Lane (NASDAQ:HLNE – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.44. The firm had revenue of $153.38 million for the quarter, compared to the consensus estimate of $102.51 million. Hamilton Lane had a return on equity of 45.45% and a net margin of 33.72%. On average, equities analysts forecast that Hamilton Lane Incorporated will post 3.61 earnings per share for the current year.
Hamilton Lane Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, January 6th. Stockholders of record on Thursday, December 15th were paid a $0.40 dividend. The ex-dividend date of this dividend was Wednesday, December 14th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.13%. Hamilton Lane’s dividend payout ratio (DPR) is currently 43.60%.
About Hamilton Lane
Hamilton Lane Incorporated is an investment firm specializing in direct and fund of fund investments. It provides following services: separate accounts (customized to each individual client and structured as single client vehicles); specialized strategies (fund-of-funds, secondaries, co-investments, taft-hartley, distribution management); advisory relationships (including due diligence, strategic portfolio planning, monitoring and reporting services); and reporting and analytics solutions.
- Get a free copy of the StockNews.com research report on Hamilton Lane (HLNE)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Hamilton Lane Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hamilton Lane and related companies with MarketBeat.com's FREE daily email newsletter.